Rosiglitazone (BRL 49653, BRL49653)_{，也称罗格列酮，是噻唑烷二酮类胰岛素增敏剂，是选择性的，具有口服活性的PPARγ激动剂，对PPARγ1、PPARγ2和PPARγ的EC50值分别为30 nM、100 nM和60 nM。Rosiglitazone与PPARγ结合，Kd约为40 nM。Rosiglitazone也是TRPC5的激活剂(EC50=30 μM)和TRPM3的抑制剂。}

客户使用本产品发表的文献：

[1] Shiqi Liu, Shiyuan Hua,et al.Production of sodium alginate-gelatin composite hydrogel-based 3D cultured fat with low cholesterol and high polyunsaturated fatty acids.Food Hydrocolloids,Volume 154,2024,110156,ISSN 0268-005X,https://doi.org/10.1016/j.foodhyd.2024.110156.(IF=11.0)

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。

[1]. Lehmann JM, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995 Jun 2;270(22):12953-6.

[2]. Willson TM, et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem. 1996 Feb 2;39(3):665-8.

[3]. Thouennon E, et al. Rosiglitazone-activated PPARγ induces neurotrophic factor-α1 transcription contributing to neuroprotection. J Neurochem. 2015 Aug;134(3):463-70.

[4]. Majeed Y, et al. Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels. Mol Pharmacol. 2011 Jun;79(6):1023-30.

[5]. Ateyya H, et al. Beneficial effects of rosiglitazone and losartan combination in diabetic rats. Can J Physiol Pharmacol. 2018 Mar;96(3):215-220.